Impact of vitamin D on spirometry findings and quality of life in patients with chronic obstructive pulmonary disease: a randomized, double-blinded, placebo-controlled clinical trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

The aim of the current study was to assess the role of vitamin D3 on quality of life and pulmonary function in patients with COPD.

Why It Was Studied

COPD is an irreversible chronic illness with airflow limitation.

A randomized, double-blinded clinical trial was conducted in 63 patients with COPD.

Who Took Part

The abstract describes 63 patients taking part.

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

Some patients received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

What Was Measured

PubMed files the paper under topics including Cholecalciferol, Dietary Supplements, Disease Progression, Forced Expiratory Volume, Iran, Lung and Pulmonary Disease, Chronic Obstructive.

The authors tagged it with the keywords 25-hydroxyvitamin D3, airflow obstruction and life quality.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 63 patients.

The publication is from 2019 (International journal of chronic obstructive pulmonary disease), a journal based in New Zealand.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.